⌕
Absci · ABSI · Nasdaq
Tenet 39 · Weak
Compare
$7.58+1.40%At closeTenet 39 · Weak
$7.58+0.11 (+1.40%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Absci (ABSI) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ABSI's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 12, 2026 · 12:48 ET
Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript

Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript…

ABSI +1.4% todayRead at source ↗
● MarketBeatNov 12, 2026 · 11:16 ET
Absci Q3 Earnings Call Highlights

Absci NASDAQ: ABSI expects to release interim data from its experimental pattern hair loss treatment in December, followed by a fuller assessment in early 2027, executives said during the company's third-quarter business…

ABSI +1.4% todayRead at source ↗
● Zacks Investment ResearchNov 12, 2026 · 09:35 ET
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago.…

ABSI +1.4% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results

ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month…

ABSI +1.4% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline

Global commercial executive brings a track record of launching prescription biologics and building consumer-driven brands at Galderma, Allergan and GSK Global commercial executive brings a track record of launching presc…

ABSI +1.4% todayRead at source ↗
● Seeking AlphaNov 11, 2026 · 17:19 ET
Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript…

ABSI +1.4% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announc…

ABSI +1.4% todayRead at source ↗
● GlobeNewsWireOct 13, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026

VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announc…

ABSI +1.4% todayRead at source ↗
● Defense WorldOct 8, 2026 · 04:15 ET
Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)

Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses bas…

ABSI +1.4% todayRead at source ↗
● GlobeNewsWireSep 24, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER…

ABSI +1.4% todayRead at source ↗
● Defense WorldSep 21, 2026 · 06:15 ET
Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrast

Silence Therapeutics (NASDAQ: SLN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the stre…

ABSI +1.4% todayRead at source ↗
● Defense WorldSep 21, 2026 · 02:45 ET
Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN)

Valneva (NASDAQ: VALN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of t…

ABSI +1.4% todayRead at source ↗
● Seeking AlphaSep 16, 2026 · 15:51 ET
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

ABSI +1.4% todayRead at source ↗
● Seeking AlphaSep 8, 2026 · 15:51 ET
Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)

Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing [2–3 injections per 6 mo…

ABSI +1.4% todayRead at source ↗
● Defense WorldSep 4, 2026 · 03:26 ET
Absci Corporation $ABSI Shares Bought by Bank of America Corp DE

Bank of America Corp DE raised its holdings in Absci Corporation (NASDAQ: ABSI) by 55.2% in a recent quarter, according to its most recent 13F filing with the SEC. The fund owned 487,193 shares of the company's stock aft…

ABSI +1.4% todayRead at source ↗
● GlobeNewsWireSep 1, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Sept.…

ABSI +1.4% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just ABSI · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.